Better Treatment Option for some Low-Grade Glioma Patients Becomes a Reality

March 16 marked a historic day for the pediatric brain cancer community with the passing of the first-ever drugs approved by the FDA to treat children with certain types of brain cancer. The two approved drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), created and manufactured by pharmaceutical company, Novartis, were authorized to be used in combination in first-line treatment of low-grade glioma (LGG) with a BRAF V600E mutation in kids one year and up. This came after the TADPOLE trial showed an overall response rate of 47% and median progression-free survival of 20.1 months for the Tafinlar + Mekinist combination compared to 11% overall response rate and 7.4 months for standard of care, according to Novartis


It is important to note that until last week, there had never been any drugs approved specifically for use in children battling pediatric brain cancer. The additional approval of the two drugs in liquid form is another win, as it provides an accessible option to patients as young as one year old. Dr. Brian Rood, Director, Clinical Neuro-Oncology, Medical Director, Brain Tumor Institute, and LBF Scientific advisor, said in a statement, “Over the past several years, the promise of molecularly targeted therapy has begun to be realized in the treatment of BRAF-altered pediatric low-grade glioma. The FDA approval of Dabrafenib and Trametinib for a subset of LGG represents a milestone in the advancement of treatment for these tumors, one that we hope will be just the first for these types of drugs for pediatric brain tumor therapy.” 


While this milestone is historic and shows the progress being made for our smallest warriors battling the deadliest disease in children, there is still more work to do. The Lilabean Foundation for Pediatric Brain Cancer Research (LBF) is proud to support collaborative research efforts for all types of childhood brain cancer. While LBF is hopeful that this is the beginning of many breakthroughs in the pediatric brain cancer space, it is important to note that there are many different types of brain cancer that affect children and over 100 subtypes. Certain brain cancers, such as Diffuse Intrinsic Pontine Glioma (DIPG), Glioblastoma Multiforme (GBM), and others, still have no cure and are fatal to 99% of children diagnosed. We celebrate this milestone but understand there is still more work to do. 


The approval of these drugs offers hope for a future where there are treatment options and personalized medicine for ALL children diagnosed with pediatric brain cancer. Founder and Executive Director Nicole Giroux said in a statement, “The recent approval by the FDA of Tafinlar + Mekinist shows that we, as a pediatric brain cancer community, are making strides towards our common goal of safer and more effective treatment options. For 12 years, LBF has been dedicated to evaluating research and clinical trials for childhood brain cancer. This FDA approval gets us one step closer to not just saving lives but to giving our children a chance to both survive AND thrive.”

Kickin' It for Kasey How One High School Student Council Turned School Spirit into Purpose text
May 8, 2026
May is Brain Cancer Awareness Month — a time to honor the children and families fighting and to celebrate the communities rallying behind them. It feels fitting, then, to share a story that moved us deeply last month.
A blue graphic with yellow text reading:
April 3, 2026
When Justine Carr laces up her running shoes and crosses the finish line of the Bend Half Marathon this spring, she'll be carrying more than miles in her legs. She'll be carrying the memory of a little girl who danced, told jokes, asked questions, and showed up every single day with a smile that could fill a room. Cameron Corno was Justine's kindergarten student and one of the bravest people Justine has ever known. Cameron passed away on June 6, 2025, after a five-year battle with ependymoma, an aggressive pediatric brain cancer. She was six years old. But in the years since Justine first set her goal to run a race in all 50 states, Cameron's spirit has quietly shaped that mission into something far greater than a personal achievement. Bend, Oregon, will be state #47. And Justine is running it — as she has before — for Cam.
Text reading
March 31, 2026
This Women's History Month, the Lilabean Foundation honors the extraordinary women who surround children fighting brain cancer — from researchers driving collaboration to friends who simply refuse to let go. Every March, the world pauses to honor the women who have shaped history — the pioneers, the trailblazers, the voices that refused to be silenced. But some of the most extraordinary women doing the most extraordinary work don't make headlines. They make meals. They make calls. They make sure that a mother caring for her sick child has someone to talk to. Behind every child fighting for their life is a remarkable network of women — researchers who build bridges between science and hope, and friends who simply refuse to let go. Their work looks different. Their titles are different. But the thread connecting them is the same: an unwillingness to accept the status quo, and an insistence on showing up. This Women's History Month, the Lilabean Foundation is honored to highlight two of those women. Gerri Trooskin, Director of Partnerships at the Children's Brain Tumor Network, who works every day to ensure that no child's experience is lost and that the science of healing moves faster because people choose to collaborate rather than compete. And Alexandra Byrnes, LBF Board Member and close friend of Stewi Corno, mother to LBF Hero Cameron Corno, who knows firsthand what it means to show up when the stakes could not be higher. Together, their stories paint a portrait of what it looks like when women lead with purpose.
SHOW MORE